AMYLIN HAS THE RIGHT NOMINEES TO LEAD THE COMPANY
As your Company's opportunities have grown over the past few years, we have spent considerable time evaluating Board composition to enhance stockholder value. In fact, since 2005, half of the Board has changed, with six new Directors joining.
In addition, this year we have put up for election two new nominees: Paul N. Clark, former Chairman, Chief Executive Officer and President of Icos Corporation, and Paulo F. Costa, former President and Chief Executive Officer of Novartis U.S. Corporation. Both are widely respected business leaders with valuable commercial and operational expertise in the biopharmaceutical industry - expertise that many of our shareholders indicated would be desirable additions to strengthen the Amylin Board.
YOUR CURRENT BOARD HAS THE NECESSARY DIABETES KNOWLEDGE TO ENHANCE STOCKHOLDER VALUE
The upcoming submission of exenatide once weekly for approval is one of the most critical points in Amylin's commitment to improving diabetes treatment. Ironically, two dissident shareholders, Carl Icahn and Eastbourne Capital Management L.L.C., have chosen this particular juncture to attempt to replace all of your Directors who have requisite diabetes business experience (other than your Company's CEO) and Directors who are also leaders in the diabetes medical community. These highly-qualified Directors would be replaced by individuals who have NO relevant diabetes experience. Such action demonstrates the dissidents' fundamental lack of understanding of your Company's business and is clearly not in the best interests of all Amylin stockholders.
YOUR BOARD HAS BEEN REASONABLE AND OPEN TO A RESOLUTION WITH ICAHN AND EASTBOURNE
Your Board has made repeated attem
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved